MYCN and neuroblastoma: The anti-tumoral effects of miR-186-5p have been identified by Neviani et al. [39], who showed that miR-186-5p in EVs derived from NK cells can be effectively transferred to neuroblastoma cells in which it directly targets two driving oncogenes (MYCN and AURKA).